ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

ClinicalTrials.gov ID: NCT02947347

Public ClinicalTrials.gov record NCT02947347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

Study identification

NCT ID
NCT02947347
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pharmacyclics LLC.
Industry
Enrollment
445 participants

Conditions and interventions

Interventions

  • Ibrutinib Oral Capsule Drug
  • Placebo Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 22, 2017
Primary completion
Feb 20, 2024
Completion
Jun 8, 2025
Last update posted
Mar 16, 2026

2017 – 2025

United States locations

U.S. sites
25
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
Southern Cancer Center Mobile Alabama 36526
City of Hope Duarte California 91010
Sansum Clinic Santa Barbara California 93105
UCLA Hematology/Oncology Santa Monica California 90095
Helen F. Graham Cancer Center and Research Institute Newark Delaware 19713
SCRI Florida Cancer Specialists South Fort Myers Florida 33916
Florida Cancer Affiliates Ocala Florida 34471
SCRI Florida Cancer Specialists North St. Petersburg Florida 33709
Rush University Medical Center Chicago Illinois 60612
Norton Cancer Institute Louisville Kentucky 40202
Goldschmidt Cancer Center Jefferson City Missouri 65109
Southeast Nebraska Cancer Center Lincoln Nebraska 68510
OHSU Knight Cancer Institute Beaverton Clinic Beaverton Oregon 97006
Greenville Health System Greenville South Carolina 29605
SCRI Tennessee Oncology Chattanooga Chattanooga Tennessee 37404-1108
SCRI Tennessee Oncology Nashville Nashville Tennessee 37203
Texas Oncology (Medical City) Dallas Texas 75230
Texas Oncology-Dallas Presbyterian Hospital Dallas Texas 75231
SCRI The Center For Cancer and Blood Disorders Fort Worth Texas 76104
MD Anderson Cancer Center Houston Texas 77030
Texas Oncology (Tyler) Tyler Texas 75702
Oncology and Hematology Associates of Southwest Virginia (Blacksburg) Blacksburg Virginia 24060
Swedish Cancer Institute Seattle Washington 98104
Medical Oncology Associates Spokane Washington 99208
W VA University Mary Babb Randolph Cancer Center Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 103 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02947347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 16, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02947347 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →